Leadership
Stephen Merrick President and Chief Executive Officer
James T. Harvey, Ph.D., Chief Science Officer
Christian J. Garver, CPA, Chief Financial Officer
James W. Brodack, Ph.D., Chief Regulatory Officer
NorthStar® Medical Radioisotopes is a nuclear medicine technology company committed to providing the United States with reliable and environmentally friendly radioisotope supply solutions to meet the needs of patients and to advance clinical research. The Company’s first product is the RadioGenix® System, an innovative and flexible platform technology approved by the U.S. Food and Drug Administration for the processing of non-uranium based molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), which is currently the most widely used diagnostic radioisotope for medical purposes. NorthStar’s proprietary and patented technologies include non-uranium based molybdenum-99 domestic production methods, patented separation chemistry systems, patented sterilization systems and a technology platform that potentially allows expanded product offerings to provide solutions in both the diagnostic and therapeutic markets. Founded in 2006 and based in Beloit, Wis., NorthStar Medical Radioisotopes, LLC is a wholly-owned subsidiary of NorthStar Medical Technologies, LLC.
Hendricks Holding Company is a significant investor in NorthStar.